Clinical Trial Update: Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the combination of vorinostat with idarubicin in patients with relapsed or refractory leukemia or myelodysplastic syndromes has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Idamycin (idarubicin)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Status: COMPLETED